Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. T-LITEs incorporate a small molecule-controlled switch into a conventional bispecific t-cell engaging antibody which enables precise on/off control over the timing and magnitude of redirected T-cell cytotoxic activity. Soteria was founded in 2018 with technology licensed from UC San Francisco and is based in San Mateo, California.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 1900 Alameda De Las Pulgas, San Mateo,california 94403,united States
- in****@****otx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- soteriabiotherapeutics.com
- HQ
- San Mateo, California
Soteria Biotherapeutics Questions
Soteria Biotherapeutics's website is soteriabiotherapeutics.com
Soteria Biotherapeutics's LinkedIn profile is https://www.linkedin.com/company/soteria-biotx
Soteria Biotherapeutics has
3 employees.
View email and phone details for 3
employees at Soteria Biotherapeutics.
Soteria Biotherapeutics's industry is
Biotechnology Research
Soteria Biotherapeutics's top competitors are
Antiva Biosciences, Inc.,
Arsenal Biosciences, Inc.,
Cartography Biosciences,
Bighat Biosciences,
Epibiologics,
Montara Therapeutics, Inc.,
Xaira Therapeutics,
Altos Labs,
Nitrase Therapeutics,
Rezo Therapeutics.
Soteria Biotherapeutics's support email address is info@soteriabiotx.com
Soteria Biotherapeutics's categories are Biotechnology Research
Soteria Biotherapeutics's founding year is 2018
